Bridgebio pharma reports topline results from phase 1/2 trial of investigational gene therapy for congenital adrenal hyperplasia (cah)

- increase in endogenous cortisol production achieved in all patients in higher dose cohorts of bbp-631, a result seen for the first time ever in cah patients

CAH Ratings Summary

CAH Quant Ranking